Marine Natural Products with Activities against Prostate Cancer: Recent Discoveries

Author:

Montuori EleonoraORCID,Hyde Caroline A. C.ORCID,Crea Francesco,Golding JonORCID,Lauritano ChiaraORCID

Abstract

Prostate cancer is the most common cancer in men, with over 52,000 new cases diagnosed every year. Diagnostics and early treatment are potentially hindered by variations in screening protocols, still largely reliant on serum levels of acid phosphatase and prostate-specific antigen, with tumour diagnosis and grading relying on histopathological examination. Current treatment interventions vary in terms of efficacy, cost and severity of side effects, and relapse can be aggressive and resistant to the current standard of care. For these reasons, the scientific community is looking for new chemotherapeutic agents. This review reports compounds and extracts derived from marine organisms as a potential source of new drugs against prostate cancer. Whilst there are several marine-derived compounds against other cancers, such as multiple myeloma, leukemia, breast and lung cancer, already available in the market, the presently collated findings show how the marine environment can be considered to hold potential as a new drug source for prostate cancer, as well. This review presents information on compounds presently in clinical trials, as well as new compounds/extracts that may enter trials in the future. We summarise information regarding mechanisms of action and active concentrations.

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Reference146 articles.

1. World Health Organization International Agency for Research on Cancer (IARC) (2022, December 01). GLOBOCAN 2020: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2020. Available online: https://Gco.Iarc.Fr/.

2. National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program SEER*Stat Database: NPCR and SEER Incidence—U.S (2022, November 15). Cancer Statistics Public Use Research Database with Prostate Cancer—Cancer Stat Facts—SEER 12 (1992–2022), United States Depart-Ment of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Available online: https://seer.cancer.gov/statfacts/html/prost.html.

3. ECIS—European Cancer Information System (2022, November 15). Prostate Cancer Fact Sheet in 2020. Available online: https://ecis.jrc.ec.europa.eu.

4. Survival of Male Genital Cancers (Prostate, Testis and Penis) in Europe 1999–2007: Results from the EUROCARE-5 Study;Trama;Eur. J. Cancer,2015

5. Prostate Cancer;Mazhar;Postgrad. Med. J.,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3